Tyra Biosciences (NASDAQ:TYRA – Get Rating) and Zoetis (NYSE:ZTS – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Valuation and Earnings
This table compares Tyra Biosciences and Zoetis’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tyra Biosciences||N/A||N/A||-$55.33 million||($1.25)||-11.16|
|Zoetis||$8.08 billion||9.42||$2.11 billion||$4.43||37.19|
Zoetis has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Insider and Institutional Ownership
84.6% of Tyra Biosciences shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 18.4% of Tyra Biosciences shares are held by company insiders. Comparatively, 0.1% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Tyra Biosciences and Zoetis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Tyra Biosciences and Zoetis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Tyra Biosciences presently has a consensus target price of $21.00, suggesting a potential upside of 50.54%. Zoetis has a consensus target price of $221.14, suggesting a potential upside of 34.24%. Given Tyra Biosciences’ higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Zoetis.
Zoetis beats Tyra Biosciences on 9 of the 12 factors compared between the two stocks.
About Tyra Biosciences
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.